Mina Kelleni
Impact in
-
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 11
- SARS-CoV-2 and COVID-19 Research 8
-
- Metabolism, Diabetes, and Cancer 3
- Co-authors
- Aly M. Abdelrahman (3 shared papers)Mohamed Ibrahim (2 shared papers)Ayman Geddawy (1 shared paper)Entesar F. Amin (1 shared paper)Salwa A. Ibrahim (1 shared paper)Farooq Ahmed Wani (2 shared papers)Mahrous A. Ibrahim (2 shared papers)Alaa A. Mohamed (1 shared paper)
- Journals
- Inflammopharmacology (3 papers)Biomedicine & Pharmacotherapy (2 papers)Human Vaccines & Immunotherapeutics (1 paper)Expert Review of Anti-infective Therapy (1 paper)Immunologic Research (1 paper)
- Partner nations
- EgyptSaudi ArabiaSpain
In The Last Decade
Mina Kelleni
26 papers receiving 425 citations
Peers
Comparison fields: 5 of 79
- Infectious Diseases 109
- Geriatrics and Gerontology 16
- Pharmacology 34
- Neurology 56
- Hepatology 29
Countries citing papers authored by Mina Kelleni
This map shows the geographic impact of Mina Kelleni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mina Kelleni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mina Kelleni more than expected).
Fields of papers citing papers by Mina Kelleni
This network shows the impact of papers produced by Mina Kelleni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mina Kelleni. The network helps show where Mina Kelleni may publish in the future.
Co-authors
The 9 scholars most cited alongside Mina Kelleni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 73 | |
| 2 | 2012 | 65 | |
| 3 | 2015 | 64 | |
| 4 | 2021 | 59 | |
| 5 | 2016 | 35 | |
| 6 | 2021 | 23 | |
| 7 | 2021 | 23 | |
| 8 | 2021 | 19 | |
| 9 | 2011 | 17 | |
| 10 | 2020 | 14 | |
| 11 | 2023 | 6 | |
| 12 | 2021 | 5 | |
| 13 | 2021 | 5 | |
| 14 | 2021 | 4 | |
| 15 | 2021 | 3 | |
| 16 | 2016 | 3 | |
| 17 | 2014 | 3 | |
| 18 | 2024 | 2 | |
| 19 | 2024 | 2 | |
| 20 | 2015 | 2 |
About Mina Kelleni
Mina Kelleni is a scholar working on Infectious Diseases, Molecular Biology, Endocrinology, Diabetes and Metabolism, Epidemiology and Pharmacology, having authored 33 papers that have together received 434 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (11 papers), SARS-CoV-2 and COVID-19 Research (8 papers), Liver Disease Diagnosis and Treatment (4 papers), Long-Term Effects of COVID-19 (3 papers), Metabolism, Diabetes, and Cancer (3 papers), Pharmacology and Obesity Treatment (3 papers), Vaccine Coverage and Hesitancy (2 papers) and Diabetes Treatment and Management (2 papers). The work is most often cited by research in Infectious Diseases (109 citations), Geriatrics and Gerontology (16 citations), Pharmacology (34 citations), Neurology (56 citations) and Hepatology (29 citations). Mina Kelleni has collaborated with scholars based in Egypt, Saudi Arabia and Spain. Frequent co-authors include Aly M. Abdelrahman, Mohamed Ibrahim, Ayman Geddawy, Entesar F. Amin, Salwa A. Ibrahim, Farooq Ahmed Wani, Mahrous A. Ibrahim, Alaa A. Mohamed and Wafaey Gomaa. Their work appears in journals such as Inflammopharmacology, Biomedicine & Pharmacotherapy, Human Vaccines & Immunotherapeutics, Expert Review of Anti-infective Therapy and Immunologic Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.